Tryngolza Injection, Solution
NDC Package 71860-101-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Tryngolza (olezarsen sodium) injection is tRYNGOLZA is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). This formulation utilizes a injection, solution delivery system. Marketed by Ionis Pharmaceuticals, Inc., this product is identified by NDC 71860-101 and is authorized under FDA application NDA218614.

Identification & Billing

NDC Package Code
71860-101-01
Package Description
1 SYRINGE, GLASS in 1 CARTON / .8 mL in 1 SYRINGE, GLASS
Product Code
71860-101
11-Digit Billing Format
71860010101
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Tryngolza
Non-Proprietary Name
Olezarsen Sodium
Substance Name
Olezarsen Sodium
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
OLEZARSEN SODIUM 80 mg/.8mL
Usage Information
TRYNGOLZA is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

Regulatory & Marketing

Labeler Name
Ionis Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA218614
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
12-19-2024
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 71860-101-01 identifies a specific commercial package of 1 syringe, glass in 1 carton / .8 ml in 1 syringe, glass of Tryngolza, a human prescription drug labeled by Ionis Pharmaceuticals, Inc.. This injection, solution is formulated for subcutaneous use and contains olezarsen sodium as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Ionis Pharmaceuticals, Inc. on December 19, 2024. The current certification is valid through December 31, 2026.

How is this Ionis Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 71860010101. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
71860-101-01
11-Digit CMS (5-4-2)
71860-0101-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.